Research Article

[Retracted] Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation

Figure 1

Administration of rocaglamide further prolongs graft survival. (a, b) Survival of the graft in cardiac transplantation (Kaplan–Meier plot). Recipients were treated with rocaglamide, and the heart grafts survived for 25 days (median survival). Rocaglamide treatment revealed significantly reduced inflammatory cell infiltration and protected the myocardial architecture. Photographs shown in this figure are representative of 3 animals in each group (a, b: 100x, 200x). (c) The International Society of Heart and Lung Transplantation (ISHLT) scores of the hearts, with each spot representing the score from each slice. The horizontal line represents the mean for each group ( in each group; , , and ).
(a)
(b)
(c)